| Overview |
| bs-23252R-Cy3 |
| HBEGF Polyclonal Antibody, Cy3 Conjugated |
| IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human |
| Mouse, Rat, Cow, Sheep, Pig |
| Specifications |
| Cy3 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human DTSF/HB-EGF |
| Polyclonal |
| #REF! |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 1839 |
| Q99075 |
| Secreted, Cell membrane |
| HB EGF; Diphtheria toxin receptor; DT R; DT-R; DTR; DTS; DTSF; HB-EGF; HBEGF; HBEGF_HUMAN; HEGFL; heparin binding EGF like growth factor; Heparin binding epidermal growth factor; Heparin binding epidermal growth factor like growth factor; Heparin-binding EGF-like growth factor; Proheparin binding EGF like growth factor. |
| Heparin-binding epidermal growth factor-like growth factor (HB-EGF) is a 22kDa O-glycosylated protein that is a potent mitogen and chemoattractant for vascular smooth muscle cells, fibroblasts and epithelial cells but not endothelial cells. The natural protein has an apparent molecular mass of 19-23 kDa and exists in multiple forms as a result of heterogeneous O-glycosylation and/or Nterminal truncation. HB-EGF is synthesized as a membrane-anchored precursor(proHB-EGF) that is proteolytically cleaved to release the soluble mature growth factor. The two forms are active as juxtacrine and paracrine/autocrine growth factors respectively.HB-EGF activates two EGF receptor subtypes, HER1/ErbB1 and HER4 and binds to heparan sulfate proteoglycan. |
| Application Dilution |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz